SLXN Silexion Therapeutics Corp - Ordinary Shares
$0.40
Price · Aug 19, 2026
Fundamentals as of May 19, 2026
52W Range
$0–$8
2% of range
Analyst Rating
BUY
8 analysts
Price Target
$60
+14825% upside
P/E (TTM)
0.2
ROE
—
Net Profit Margin
—
SLXN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.40
Market Cap
—
P/E (TTM)
0.2
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $8
SLXN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
SLXN
Peer Median
P/E (TTM)
0.2
0.1
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
SLXN
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
SLXN
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
SLXN
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
SLXN
Peer Median
SLXN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
8 analysts
- Strong Buy 2 25.0%
- Buy 4 50.0%
- Hold 2 25.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-08-13
Low
$60.00
High
$60.00
Median target
$60.00
+14825.4%
Mean target
$60.00
+14825.4%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-49.2%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-8.50 | $-13.16 | 4.7% |
| Dec. 31, 2025 | $-14.00 | $-11.42 | -2.6% |
| Sept. 30, 2025 | $-28.80 | $-34.68 | 5.9% |
| June 30, 2025 | $-43.20 | $-36.72 | -6.5% |
| March 31, 2025 | $-3.90 | $-3.37 | -0.53% |
| Dec. 31, 2024 | $-311.40 | $-14.99 | -296.4% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SLXN | — | 0.2 | — | — | — | — |
| CLGN | — | — | — | — | — | — |
| GLMD | — | — | — | — | — | — |
| SCNI | — | — | — | — | — | — |
| URGN | $1.13B | — | 21.4% | -139.8% | 154.4% | 88.7% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 16
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $6M | |
| Prepaid Expense | $570.0K | |
| Other Current Assets | $49.0K | |
| Current Assets | $7M | |
| PP&E (Net) | $25.0K | |
| Total Assets | $7M | |
| Accrued Liabilities | $859.0K | |
| Current Liabilities | $3M | |
| Capital Leases | $286.0K | |
| Total Liabilities | $5M | |
| Common Stock | $42.0K | |
| Paid-in Capital | $58M | |
| Retained Earnings | $-55M | |
| Stockholders' Equity | $3M | |
| Liabilities + Equity | $7M | |
| Shares Outstanding | 3,126,651 |
Valuation (TTM) 3
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $-12M | |
| P/E | 0.2 | |
| Earnings Yield | 466.7% |
Income Statement 13
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| R&D Expense | $1M | $590.0K | |
| SG&A Expense | $1M | $1M | |
| Operating Expenses | $3M | $2M | |
| Operating Income | $-3M | $-2M | |
| Interest Income | $32.0K | $2.0K | |
| Other Non-op | $4.0K | $3.0K | |
| Pretax Income | $-3M | $-2M | |
| Net Income | $-3M | $-2M | |
| EPS (Basic) | $0.85 | $3.84 | |
| EPS (Diluted) | $0.85 | $3.84 | |
| Shares (Basic) | 3,230,378 | 451,990 | |
| Shares (Diluted) | 3,230,378 | 451,990 | |
| EBITDA | $-3M | · |
Balance Sheet 16
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Cash & Equivalents | $2M | · | |
| Prepaid Expense | $2M | · | |
| Other Current Assets | $96.0K | · | |
| Current Assets | $4M | · | |
| PP&E (Net) | $23.0K | · | |
| Total Assets | $5M | · | |
| Accrued Liabilities | $799.0K | · | |
| Current Liabilities | $4M | · | |
| Capital Leases | $251.0K | · | |
| Total Liabilities | $4M | · | |
| Common Stock | $46.0K | · | |
| Paid-in Capital | $58M | · | |
| Retained Earnings | $-58M | · | |
| Stockholders' Equity | $291.0K | · | |
| Liabilities + Equity | $5M | · | |
| Shares Outstanding | 3,126,651 | · |
Cash Flow 8
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Stock-based Comp | $345.0K | $21.0K | |
| Operating Cash Flow | $-4M | $-2M | |
| CapEx | $0 | $6.0K | |
| Investing Cash Flow | $0 | $-6.0K | |
| Stock Issued | $83.0K | $0 | |
| Net Stock Activity | $83.0K | · | |
| Financing Cash Flow | $83.0K | $7M | |
| Free Cash Flow | $-4M | · |
Profitability 2
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| ROA | -42.3% | · | |
| ROE | -190.0% | · |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Current Ratio | 1.0 | · | |
| Quick Ratio | 0.6 | · |
Valuation (TTM) 8
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Net Income TTM | $-10M | · | |
| Market Cap | $4M | · | |
| P/E | 0.1 | · | |
| P/B | 13.8 | · | |
| P / Tangible Book | 13.8 | · | |
| P / Cash Flow | -1.1 | · | |
| P / FCF | -1.1 | · | |
| Earnings Yield | 928.9% | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F)
Institutional activity — Q1 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 (-1 vs prior Q) | 0 (0 vs prior Q) | 2 (+2 vs prior Q) | 1 (0 vs prior Q) | +20K |
Compared to Q4 2025. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
Company insiders 8 insiders · 3 officers · 6 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ilan Hadar | Chairman and CEO | June 4, 2026 A | 16,547 | 0 | 0 | $0 |
| Hadar Mirit Horenshtein | CFO and Secretary | June 4, 2026 A | 12,515 | 0 | 0 | $0 |
| Mitchell Shirvan | CSO and CDO | June 4, 2026 A | 8,789 | 0 | 1 | $-31,032 |
| Amnon Peled | Director | Feb. 20, 2026 A | 8,237 | 0 | 0 | $0 |
| Dror Yosef Abramov | Director | Feb. 20, 2026 A | 10,180 | 0 | 0 | $0 |
| Avner Lushi | Director | Feb. 20, 2026 A | 25,399 | 0 | 0 | $0 |
| Shlomo Noy | Director | Feb. 20, 2026 A | 25,399 | 0 | 0 | $0 |
| Ruth Alon | Director | Feb. 20, 2026 A | 10,228 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Moringa Sponsor, LP, Moringa Partners Ltd, Ilan Levin ×3 filings | May 29, 2026 | 32.99% | Amendment | — | SEC |
| Wildcat Capital Management, LLC, Wildcat Partner Holdings, LP, Leonard A. Potter | June 26, 2025 | 1.30% | Amendment | — | SEC |
| Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP), Avner Lushi, Shlomo Noy | Nov. 20, 2024 | — | Initial filing | — | SEC |
| Wildcat Capital Management, LLC (2), Wildcat Partner Holdings, LP, Leonard A. Potter (2) | Aug. 22, 2024 | — | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.